The New Artificial Intelligentsia
By Ruha Benjamin,
Los Angeles Review of Books
| 10. 18. 2024
IN THE FALL OF 2016, I gave a talk at the Institute for Advanced Study in Princeton titled “Are Robots Racist?” Headlines such as “Can Computers Be Racist? The Human-Like Bias of Algorithms,” “Artificial Intelligence’s White Guy Problem,” and “Is an Algorithm Any Less Racist Than a Human?” had captured my attention in the months before. What better venue to discuss the growing concerns about emerging technologies, I thought, than an institution established during the early rise of fascism in Europe, which once housed intellectual giants like J. Robert Oppenheimer and Albert Einstein, and prides itself on “protecting and promoting independent inquiry.”
My initial remarks focused on how emerging technologies reflect and reproduce social inequities, using specific examples of what some termed “algorithmic discrimination” and “machine bias.” A lively discussion ensued. The most memorable exchange was with a mathematician who politely acknowledged the importance of the issues I raised but then assured me that “as AI advances, it will eventually show us how to address these problems.” Struck by his earnest faith in technology as a force for good...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Sophie Alexander and Ike Swetlitz, Bloomberg | 06.25.2025
A California-startup focused on genetically editing human embryos — a step toward creating so-called designer babies — is raising money as many of Silicon Valley’s ultra-rich turn their attention to one of the most controversial technologies in medicine.
Bootstrap Bio...